Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market
Femasys Inc. (Nasdaq: FEMY) has secured strategic distribution partnerships for its CE-marked products, including FemaSeed® and FemVue®, in Spain. The company has partnered with Comercial Medico Quirurigca, SA (CMQ) for northern Spain and Durgalab for southern Spain, marking its first EU distribution agreements. These partnerships represent a significant step in Femasys' global expansion, with a commitment to purchase a minimum of $1.3 million of FemaSeed over the next year.
Femasys CEO Kathy-Lee Sepsick emphasized the importance of these partnerships in expanding access to affordable and effective women's healthcare solutions. The distributors' expertise in women's healthcare and understanding of Femasys' infertility portfolio are expected to drive market penetration in Spain.
Femasys Inc. (Nasdaq: FEMY) ha stabilito partnership di distribuzione strategiche per i suoi prodotti con marchio CE, tra cui FemaSeed® e FemVue®, in Spagna. L'azienda ha collaborato con Comercial Medico Quirurgica, SA (CMQ) per il nord della Spagna e Durgalab per il sud della Spagna, segnando i suoi primi accordi di distribuzione nell'UE. Queste partnership rappresentano un passo significativo nell'espansione globale di Femasys, con un impegno a acquistare un minimo di 1,3 milioni di dollari di FemaSeed nell'anno successivo.
Il CEO di Femasys, Kathy-Lee Sepsick, ha sottolineato l'importanza di queste partnership per ampliare l'accesso a soluzioni sanitarie femminili efficaci ed economiche. L'expertise dei distributori nella salute delle donne e la comprensione del portafoglio di infertilità di Femasys dovrebbero favorire la penetrazione del mercato in Spagna.
Femasys Inc. (Nasdaq: FEMY) ha asegurado asociaciones estratégicas de distribución para sus productos con marca CE, incluidos FemaSeed® y FemVue®, en España. La empresa ha formado una alianza con Comercial Medico Quirurgica, SA (CMQ) para el norte de España y Durgalab para el sur de España, marcando sus primeros acuerdos de distribución en la UE. Estas asociaciones representan un paso significativo en la expansión global de Femasys, con un compromiso de compra de un mínimo de 1,3 millones de dólares en FemaSeed durante el próximo año.
La CEO de Femasys, Kathy-Lee Sepsick, enfatizó la importancia de estas asociaciones para ampliar el acceso a soluciones de atención médica femenina asequibles y efectivas. La experiencia de los distribuidores en el cuidado de la salud de las mujeres y su comprensión del portafolio de infertilidad de Femasys se espera que impulse la penetración en el mercado en España.
Femasys Inc. (Nasdaq: FEMY)는 스페인에서 FemaSeed®와 FemVue®를 포함한 CE 인증 제품의 전략적 유통 파트너십을 확보했습니다. 회사는 북부 스페인에 대해 Comercial Medico Quirurgica, SA (CMQ)와, 남부 스페인에 대해 Durgalab와 협력하여 EU 내 첫 유통 계약을 체결했습니다. 이러한 파트너십은 Femasys의 글로벌 확장에서 중요한 단계로, 향후 1년 동안 최소 130만 달러의 FemaSeed 구매를 약속합니다.
Femasys의 CEO인 Kathy-Lee Sepsick는 이러한 파트너십이 저렴하고 효과적인 여성 건강 관리 솔루션에 대한 접근성을 확대하는 데 중요하다고 강조했습니다. 유통업체의 여성 건강 관리 전문성과 Femasys의 불임 포트폴리오에 대한 이해는 스페인 시장 침투를 촉진할 것으로 기대됩니다.
Femasys Inc. (Nasdaq: FEMY) a sécurisé des partenariats de distribution stratégiques pour ses produits marqués CE, y compris FemaSeed® et FemVue®, en Espagne. L'entreprise a établi un partenariat avec Comercial Medico Quirurgica, SA (CMQ) pour le nord de l'Espagne et Durgalab pour le sud, marquant ses premiers accords de distribution dans l'UE. Ces partenariats représentent une étape significative dans l'expansion mondiale de Femasys, avec un engagement d'achat d'un minimum de 1,3 million de dollars de FemaSeed au cours de l'année à venir.
La PDG de Femasys, Kathy-Lee Sepsick, a souligné l'importance de ces partenariats pour élargir l'accès à des solutions de santé féminine abordables et efficaces. L'expertise des distributeurs dans le domaine de la santé des femmes et leur compréhension du portefeuille d'infertilité de Femasys devraient favoriser la pénétration du marché en Espagne.
Femasys Inc. (Nasdaq: FEMY) hat strategische Vertriebsvereinbarungen für seine CE-zertifizierten Produkte, einschließlich FemaSeed® und FemVue®, in Spanien gesichert. Das Unternehmen hat Partnerschaften mit Comercial Medico Quirurgica, SA (CMQ) für Nordspanien und Durgalab für Südkalifornien geschlossen, was die ersten Vertriebsvereinbarungen der EU für das Unternehmen markiert. Diese Partnerschaften stellen einen bedeutenden Schritt in der globalen Expansion von Femasys dar, mit einem festen Kaufversprechen von mindestens 1,3 Millionen Dollar für FemaSeed im kommenden Jahr.
Kathy-Lee Sepsick, CEO von Femasys, betonte die Bedeutung dieser Partnerschaften für den Ausbau des Zugangs zu erschwinglichen und effektiven Lösungen im Bereich der Frauengesundheit. Das Fachwissen der Vertriebspartner im Bereich Frauengesundheit und ihr Verständnis des Femasys-Portfolios zur Unfruchtbarkeit sollen die Marktdurchdringung in Spanien vorantreiben.
- Secured distribution partnerships for CE-marked products in Spain, the first EU country
- Minimum purchase commitment of $1.3 million for FemaSeed over the next year
- Expansion into the European market with potential for further growth
- Partnership with experienced distributors in women's healthcare
- None.
Insights
The strategic distribution partnerships for FemaSeed® in Spain represent a significant milestone for Femasys. With a
The expansion into the Spanish market, as the first EU country for distribution, opens doors for potential growth across Europe. This move diversifies Femasys' revenue sources and reduces dependence on a single market, which is generally viewed positively by investors.
However, it's important to note that while
Femasys' entry into the Spanish market with FemaSeed® and FemVue® is strategically sound. These products address the growing demand for affordable fertility treatments, positioning Femasys well in a market seeking alternatives to costly IVF procedures.
The partnership with established distributors like CMQ and Durgalab is crucial. Their expertise in women's healthcare and strong local presence can accelerate market penetration. The CE mark under MDR adds credibility and facilitates easier expansion to other EU countries.
However, competition in the fertility market is intense. Femasys must demonstrate clear clinical advantages and cost-effectiveness to gain significant market share. The success in Spain could serve as a proof of concept for other European markets, potentially attracting more distributors and investors.
Company taps Comercial Medico Quirurigca, SA and Durgalab as first EU distributors for its CE-marked women’s reproductive healthcare products
ATLANTA, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces that the Company has secured strategic distribution partnerships for its CE-marked products, including FemaSeed® and FemVue® in Spain. Comercial Medico Quirurigca, SA (CMQ) will distribute the products in northern Spain and Durgalab will distribute them in the south. Spain is the first EU country where the Company has identified distributors and began marketing its products.
Kathy-Lee Sepsick, Femasys Founder and CEO commented, “Today’s announcement marks a significant step in our global expansion and reinforces our mission to empower women across the world with new, innovative and superior healthcare solutions. Our distribution partners have extensive expertise in women’s healthcare and a strong understanding of the value of our infertility portfolio. Their commitment to purchase a minimum of
“It is an honor to partner with Femasys to bring the latest technology for infertility treatment that is more cost-effective than IVF or ICSI and an improvement to traditional IUI to the Spain market,” said Jordi Pié, CMQ’s Founder and CEO. “We have been preparing as we awaited the availability of Femasys’ products with the CE mark under MDR and are thrilled to provide FemaSeed along with the other diagnostic products.”
About Spanish Infertility Market
According to the European registries by the European Society of Human Reproduction and Embryology (ESHRE)1, Spain has the most in vitro fertilization (IVF) clinics with 244 facilities in Europe. Additionally, Spain ranks second in intrauterine (IUI) insemination cycles using husband sperm and holds the top position for IUI cycles using donor sperm.
_______________
1 ART in Europe, 2019: results generated from European registries by ESHRE, Human Reproduction, 2023, 38(12), 2321–2338, https://doi.org/10.1093/humrep/dead197, October 17, 2023.
About Femasys
Femasys is a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic solutions, including a lead revolutionary product candidate and FDA-cleared products. FemaSeed® Intratubal Insemination, an innovative infertility treatment designed to deliver sperm directly where conception occurs, is FDA-cleared and has received regulatory approval in Canada and Europe. FemBloc® permanent birth control in late-stage clinical development is the first and only non-surgical, in-office, permanent birth control method intended to be a safer option for women at substantially less cost than the long-standing surgical alternative. The Company has developed diagnostic products that are complementary for which it has achieved regulatory approvals to market in the U.S., Canada, Europe, and other ex-U.S. territories, and which are commercial-ready due to its in-house manufacturing capabilities. Its diagnostic products include FemVue® and FemVue® MINI for fallopian tube assessment by ultrasound, which can be used in conjunction with FemCath®, an intrauterine catheter for selective fallopian tube evaluation, and FemCerv®, an endocervical tissue sampler for cervical cancer diagnosis. Learn more at www.femasys.com, or follow us on X, Facebook and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “pending,” “intend,” “believe,” “suggests,” “potential,” “hope,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to develop and advance our current product candidates and programs into, and successfully initiate, enroll and complete, clinical trials; the ability of our clinical trials to demonstrate safety and effectiveness of our product candidates and other positive results; estimates regarding the total addressable market for our products and product candidates; our ability to commercialize our products and product candidates, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.
Contacts:
Investors:
CORE IR
Matt Blazei
IR@femasys.com
Media:
CORE IR
Kati Waldenburg
Media@femasys.com
FAQ
What products will Femasys distribute in Spain through its new partnerships?
How much is the minimum purchase commitment for FemaSeed in Spain?
Which companies are Femasys' distribution partners in Spain?
Is Spain the first European Union country where Femasys (FEMY) has secured distributors?
